,0,1,2,3,4,5,6,7,8
0,YOURLAB,,"Accession ID:NGSO-221209001
Patient Name: LAN ZHENG,MEI-CHAN
Diagnosis: gastric cancer",,,,Page 6 of 76,,
1,Gene/Variant,,Allelic Fraction,Function,Classification,Assessment,,,
2,"p.N31K
g.47373479C>G",,,,,,,,
3,"ERBB2
c.346G>A
p.VI16M
g.39708441G>A",,"47.0% (of 459
reads)",loss,Tier 3,Uncertain Significance,,,
4,"ERBB3
c.3380G>A
p.R1127H
g.56101239G>A",,"48.0% (of 629
reads)",normal,Tier 3,Uncertain Significance,,,
5,"ERCC5
c.2108A>G
p.D703G
g.102865820A>G",,"48.0% (of 238
reads)",normal,Tier 3,Uncertain Significance,,,
6,"FAT1
c.3337G>A
p.D1ll3N
g.186663542C>T",,38.0% (of 219 reads),loss,Tier 3,Uncertain Significance,,,
7,"FGFR4
c.1871A>C
p.N624T
g.177096106A>C",,"48.0% (of 145
reads)",normal,Tier 3,Uncertain Significance,,,
8,"FUBP1
c.733C>G
p.Q245E
g.77964872G>C",,52.0% (of 221 reads),loss,Tier 3,Uncertain Significance,,,
9,"HLA-A
c
538_539delTTinsCA
p.L180Q
g.29943462_299434
63delTTinsCA",,100.0% (of 63 reads),,Tier 3,Uncertain Significance,,,
10,"HLA-A
C.
559_560delACinsCG
p.T187R
g.29943483_299434
84delACinsCG",,54.0% (of 119 reads),normal,Tier 3,Uncertain Significance,,,
11,"HLA-A
C.
570_571delGTinsCG
p.
E190_W191delinsDG",,45.0% (of 152 reads),loss,Tier 3,Uncertain Significance,,,
12,YOURLAB,"Accession ID:NGSO-221209001
Patient Name: LAN ZHENG,MEI-CHAN
Diagnosis: gastric cancer",,Approved Therapies,,Page 5 of 76,,,
13,Gene/Variant,Allelic Fraction,Gastric Cancer,Other Indications,"Associated With
Resistance","Clinical
Trials",,,
14,,,,"pertuzumab
trastuzumab
emtansine
tucatinib",,,,,
15,"ERBB3
p.R1127H
g.56101239G>A
Tier 3
Uncertain
Significance",48.0% (of 629,,"afatinib
dacomitinib
neratinib
osimertinib
osimertinib",,,,,
16,"FGFR4
c.1871A>C
p.N624T
g.177096106A>C
Tier 3
Uncertain
Significance",48.0% (of 145 reads),,"erdafitinib
futibatinib
infigratinib
lenvatinib
ponatinib
regorafenib",,,,,
17,"JAK3
c.2660G>A
p.R887H
g.17832539C>T
Tier 3
Uncertain
Significance","58.0% (of262
reads)",,ruxolitinib,,,,,
18,Variants of Unknown Clinical Significance,,,,,,,,
19,Gene/Variant,Allelic Fraction,Function,Classification,Assessment,,,,
20,"AMERT
c.1646G>A
p.R549Q
g.64191641C>T",6.43% (of 311 reads),normal,Tier 3,Uncertain Significance,,,,
21,"CRLF2
c.29C>T
p.P1OL
g.1202520G>A","43.0% (of 326
reads)",loss,Tier 3,Uncertain Significance,,,,
22,"EPCAM
c.93C>G",36.0% (of 163 reads),normal,Tier 3,Uncertain Significance,,,,
23,"YOURLAB
Test Performed: Somatic Panel


Patient Name LAN ZHENG,MEI-

Date of Birth Nov 25,1935




Result:
6
Clinically Significant
Variants
Biomarker Findings","1700 Lincoln Blvd, Suite 20, Redwood City, CA 94063
labxyz.com/(650)4844040


Patient
CHAN
Age 87
Sex Female
Ethnicity East Asian
Diagnosis gastric cancer
Positive","14
Therapies Associated with
Resistance","Client AN,HE
Client ID 037658
Physician JANG,REN-CHIN
Pathologist","Client
76
Therapies with Potential
Clinical Benefit",,"Report Date Dec 19,2022

Accession ID NGSO-221209001
Specimen
Collection Dec 9,2022
Accession Dec 20,2022
Primary Tumor Site Stomach
Clinical Trials","Status-
Specimen",
24,,,"Approved Therapies in Gastric
Cancer",,,"Approved Therapies in Other
Indications",,,"Clinical
Trials"
25,"Tumor Mutation Burden:
TMB-low (2.78 Mutations
/Megabase)
Tier 2C",,,,,"cetuximab
ipilimumab/nivolumab",,,
26,"Microsatellite Status:
MS-stable
Tier 2C",,,,,"5-fluorouracil
5-fluorouracil/leucovorin
5-fluorouracil/leucovorin/oxaliplatin
capecitabine
capecitabine/oxaliplatin
cetuximab
fluoropyrimidine
lenvatinib/pembrolizumab",,,6
27,Actionable Variants With Associated Therapies,,,,,Approved Therapies,,,
28,Gene/Variant,Allelic Fraction,,Gastric Cancer,,Other Indications,"Associated With
Resistance",,"Clinical
Trials"
29,"CDKN2A
c.247C>T
p.H83Y
g.21971112G>A
Tier 2C
Pathogenic","9.22% (of 206
reads)",,,,,,,2
30,YOURLAB,"Accession ID: NGSO-221209001
Patient Name: LAN ZHENG,MEI-CHAN
Diagnosis: gastric cancer",,Approved Therapies,,Page 2 of 76,,,
31,"Gene/Variant
KRAS
c.35G>C
p.G12A
g.25245350C>G
Tier 2C
Pathogenic","Allelic Fraction
39.0% (of 160 reads)",Gastric Cancer,"Other Indications
5-fluorouracil
Virinotecan
/leucovorin
5-fluorouracil
/leucovorin
/oxaliplatin
aflibercept
atezolizumab
bevacizumab
binimetinib
capecitabine
/oxaliplatin
carboplatin
/gemcitabine
carboplatin
/paclitaxel
cisplatin
/docetaxel
cisplatin
/gemcitabine
cisplatin
/paclitaxel
cisplatin
/pemetrexed
cobimetinib
docetaxel
fluoropyrimidine
gemcitabine
paclitaxel
pemetrexed
ramucirumab
regorafenib
selumetinib
sotorasib
tipiracil
trametinib","Associated With
Resistance
EGFR tyrosine
kinase inhibitor
afatinib
cisplatin
crizotinib
erlotinib
gefitinib
osimertinib
panitumumab
vinorelbine","Clinical
Trials",,,
32,YOURLAB,"Accession ID:NGSO-221209001
Patient Name: LAN ZHENG,MEI-CHAN",Diagnosis: gastric cancer,,Approved Therapies,,Page 4of 76,,
33,Gene/Variant,Allelic Fraction,,Gastric Cancer,"Other Indications
lenalidomide
/rituximab
obinutuzumab
obinutuzumab
/venetoclax
ofatumumab
rituximab
rituximab
/venetoclax
venetoclax
zanubrutinib","Associated With
Resistance","Clinical
Trials",,
34,"ERBB2
p.V116M
g.3970844lG>A
Tier 3
Uncertain
Significance","47.0% (of 459
p.V116M",,trastuzumab,"afatinib
carboplatin
/gemcitabine
carboplatin
/paclitaxel
cisplatin
/docetaxel
cisplatin
/gemcitabine
cisplatin
/paclitaxel
cisplatin
/pemetrexed
dacomitinib
docetaxel
erlotinib
gemcitabine
lapatinib
margetuximab
mobocertinib
neratinib
osimertinib
paclitaxel
pemetrexed",,,,
35,YOURLAB,"Accession ID: NGSO-221209001
Patient Name: LAN ZHENG,MEI-CHAN
Diagnosis: gastric cancer",,Approved Therapies,,,Page 3 of 76,,
36,Gene/Variant,Allelic Fraction,Gastric Cancer,Other Indications,"Associated With
Resistance","Clinical
Trials",,,
37,"MRE11
c.689C>T
p.P230L
g.94471730G>A
Tier 2C
Likely Pathogenic","50.0% (of 229
reads)",,,,2,,,
38,"POLE
p.V1446fs*3
g.132643513_132643
514de|CA
Tier 2C
Pathogenic","2.88% (of 139 reads)
Tier 2C",trifluridine,"cladribine
cytarabine",,"clofarabine
daunorubicin",,,
39,"RNF43
c.813_825de|GTGTG
CCATCTGT
p.C272fs*143
g.58360807_583608
19delACAGATGGCA
CAC
Tier 2C
Likely Pathogenic",7.71% (of 441 reads),,,,,,,
40,"TP53
c.743G>A
p.R248Q
g.7674220C>T
Tier 2C
Pathogenic",8.13%(of246 reads),,"acalabrutinib
acalabrutinib
/obinutuzumab
alemtuzumab
alemtuzumab
/rituximab
bortezomib
/rituximab
decitabine
duvelisib
fludarabine
phosphate
ibrutinib
idelalisib
idelalisib
/rituximab
lenalidomide","chlorambucil
fludarabine
lenalidomide
rituximab",2,,,
